

Dear Meindert,

Nurses working in this area of health have been invited by the RCN to be become a formal consultee for Vemurafenib for the treatment of unresectable locally advanced or metastatic BRAFV600 mutation-positive malignant melanoma . However, currently the RCN will not be making any clinical expert nominations and we will fax you the form for participation shortly.

Thank you for providing us with the opportunity to nominate a clinical expert for the above-mentioned topic.

Please acknowledge receipt.